COMPANY SECRETARY ACS: 11963 CP: 3460 Mobile: 98480 - 59315 E-mail: prenukaacs@gmail.com

## Secretarial Compliance Report of M/s. Suven Life Sciences Limited for the year ended 31/03/2022

## I, D. Renuka have examined:

- (a) all the documents and records made available to us and explanation provided by **Suven** Life Sciences Limited ("the listed entity").
- (b) the filings /submissions made by the listed entity to the stock exchanges,
- (c) website of the listed entity,
- (d) any other document/filing, as may be relevant, which has been relied upon to make this certification.

for the year ended 31/03/2022 ("Review Period") in respect of compliance with the provisions of:

- (a) The Securities and Exchange Board of India Act,1992 ("SEBI Act") and the Regulations, circulars, guidelines issued there under; and
- (b) The Securities Contracts (regulation) Act,1956 ("SCRA"),rules made there under and the Regulations, circulars, guidelines issued there under by the Securities and Exchange Board of India ("SEBI");

The specific Regulations, whose provisions and the circulars/ guidelines issued thereunder, have been examined, include:-

- (a) Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015;
- (b) Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018;
- (c) Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
- (d) Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018;(Not applicable to the listed entity during the review period)
- (e) Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014;
- (f) Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008;(Not applicable to the listed entity during the review period)
- (g) Securities and Exchange Board of India (Issue and Listing of Non-Convertible and redeemable Preference Share) Regulations, 2013; (Not applicable to the listed entity during the review period)
- (h) Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, vol.

## OFFICE:

And based on the above examination, I hereby report that, during the Review Period:

(a) The listed entity has complied with the provisions of the above regulations and circulars/ guidelines issued thereunder, except in respect of matters specified below:-

Sr. No	Compliance requirement (Regulations/Circulars/guid elines including specific clause)		Observations/Remarks of the Practicing Company Secretary.			
Nil						

- (b) The listed entity has maintained proper records under the provisions of the above regulations and circulars/ guidelines issued thereunder in so far as it appears from my/our examination of those records.
- (c) The following are the details of actions taken against the listed entity / its promoters/directors/material subsidiaries either by SEBI or by Stock Exchanges (including under the standard operating procedures issued by SEBI through various circulars) under the aforesaid Acts/ Regulations and circulars/ guidelines issued thereunder:

Sr No	Action taken	Details of violation	Details of action taken	Observations/	
	by		e.g. fines, warning	remarks of the	
			letter,debarrment,etc.	practicing	
			*	Company	
			* *	Secretary, if	
			20 N	any.	
Nil					

(d) The listed entity has taken the following actions to comply with the observations made in previous reports:

Sr No.	Observations of the Practicing Company Secretary in the previous reports	Observation made in the secretarial compliance report for the year ended(The years are to be mentioned)	Actions taken by the listed entity, if any	Comments of the Practicing Company Secretary on the on the action taken by the listed entity		
Not Applicable						

Place: Hyderabad Date: 24/05/2022

DRENUKA ACS: 11963, CP NO: 3460 SE

Signature Hyderabac

UDIN: A011963D000375073

ICSI Peer Review UIN: I2000TL172900